Objectives The aim of this single‐center chart review was to quantify the hematologic
response and validated reported outcomes with voxelotor treatment. Methods Real‐world …

Patients with sickle cell disease (SCD) experience a range of clinical symptoms, including
acute and chronic pain, fatigue, and respiratory problems, as well as chronic organ …

Background: Sickle cell disease (SCD) is a lifelong, inherited disorder characterized by
mutations in the hemoglobin (Hb) subunit β gene that leads to the production of sickle …

Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

Objective: To review the pharmacological characteristics, clinical evidence, and place in
therapy of voxelotor for the treatment of sickle cell disease (SCD). Data Sources: A …

New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …

Background Sickle cell disease (SCD) is a genetic disease that impacts patients' quality of
life, healthcare costs, and life expectancy. Elevated sickle hemoglobin (HbS), which readily …

In 2019 voxelotor was approved by the United States Food and Drug Administration for the
treatment of sickle cell disease (SCD) in patients≥ 16 years. The HOPE trial showed that …

Background For decades, patients with sickle cell disease have had only a limited number of
therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin …

Introduction Sickle cell disease (SCD) describes a group of heritable blood disorders
caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to …